RVMD Insider Trading
Insider Ownership Percentage: 8.00%
Insider Buying (Last 12 Months): $59,999,962.00
Insider Selling (Last 12 Months): $10,871,731.20
Revolution Medicines Insider Trading History Chart
This chart shows the insider buying and selling history at Revolution Medicines by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Revolution Medicines Share Price & Price History
Current Price: $42.34
Price Change: ▲ Price Increase of +0.87 (2.10%)
As of 02/19/2025 05:00 PM ET
Revolution Medicines Insider Trading History
SEC Filings (Institutional Ownership Changes) for Revolution Medicines (NASDAQ:RVMD)
94.34% of Revolution Medicines stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at RVMD by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Revolution Medicines Institutional Trading History
Data available starting January 2016
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Read More on Revolution Medicines
Today's Range
Now: $42.34
52 Week Range
Now: $42.34
Volume
733,642 shs
Average Volume
1,291,792 shs
Market Capitalization
$7.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.45
Who are the company insiders with the largest holdings of Revolution Medicines?
Revolution Medicines' top insider shareholders include:
- Thilo Schroeder (Director)
- Mark A Goldsmith (Insider)
- Stephen Michael Kelsey (Insider)
- Margaret A Horn (COO)
- Jack Anders (CFO)
- Margaret A Horn (Insider)
- Jeff Cislini (General Counsel)
- Sushil Patel (Director)
- Barbara Weber (Director)
Learn More about top insider investors at Revolution Medicines.
Who are the major institutional investors of Revolution Medicines?
Which institutional investors are selling Revolution Medicines stock?
Within the last quarter, RVMD stock was sold by these institutional investors:
- Wellington Management Group LLP
- Soleus Capital Management L.P.
- Bellevue Group AG
- Casdin Capital LLC
- Fred Alger Management LLC
- Balyasny Asset Management L.P.
- Avidity Partners Management LP
- Alphabet Inc.
In the last year, company insiders that have sold Revolution Medicines company stock include:
- Thilo Schroeder (Director)
- Mark A Goldsmith (Insider)
- Stephen Michael Kelsey (Insider)
- Margaret A Horn (COO)
- Jack Anders (CFO)
- Margaret A Horn (Insider)
- Jeff Cislini (General Counsel)
Learn More investors selling Revolution Medicines stock.
Which institutional investors are buying Revolution Medicines stock?
In the last quarter, RVMD stock was purchased by institutional investors including:
- Boxer Capital Management LLC
- Janus Henderson Group PLC
- Vanguard Group Inc.
- Farallon Capital Management LLC
- Norges Bank
- Nextech Invest Ltd.
- Paradigm Biocapital Advisors LP
- FMR LLC